RSAR: Post-marketing RX Drug Abuse Surveillance Data - IBH (Data Source)

The contract involves the recompete of a project focused on post-marketing prescription drug abuse surveillance data, managed by the Food and Drug Administration (FDA). It is identified under the NAICS code 541990, indicating it falls within professional, scientific, and technical services. The purpose is to continue collecting and analyzing data related to prescription drug abuse after their market release, supporting public health and regulatory efforts. This data source initiative is critical for monitoring drug safety and informing policy decisions. The opportunity is currently forecasted with no designated set-aside status or specific solicitation number provided, and detailed location information for performance is not specified. The FDA is the contracting agency, with primary points of contact including the CDER Acquisition Liaison and a contracting officer yet to be determined. Interested parties can reach out via the provided email for acquisition-related inquiries. This recompete is expected to be active in fiscal year 2026, signaling the FDA’s ongoing commitment to addressing prescription drug abuse through robust data collection and surveillance.